News
The star of GSK’s Hengrui partnership is the COPD candidate HRS-9821, which will complement the pharma’s respiratory pipeline ...
Health Secretary Robert F. Kennedy Jr. wants to remove all members of the USPSTF for being too “woke,” according to reporting by the Wall Street Journal. An HHS spokesperson, however, says there has ...
Brazilian authorities said the death was unlikely to have been caused by Elevidys and was instead more in line with severe ...
Despite the failure of its Recognify-partnered inidascamine, Jefferies analysts do not expect a definitively negative stock ...
The Commissioner’s National Priority Vouchers aim to offer accelerated pathways to drugs that meet certain criteria, perhaps ...
These five upcoming data drops could usher in more effective and convenient therapies for Alzheimer’s disease and open up ...
Acknowledging the limits of disease-modifying drugs like Leqembi and Kisunla, companies like Bristol Myers Squibb, Acadia, ...
The company didn’t share specific data for the molecule, gefurulimab, but said it hit all endpoints in the Phase III PREVAIL ...
To meet the requirements for FDA Breakthrough Device Designation, CDx Diagnostics submitted technical and clinical evidence ...
The European Union’s health regulatory agency did not endorse approving Elevidys for ambulatory patients with Duchenne ...
The strategic reprioritization comes after the company hit two major hurdles in the past year, including a clinical hold for ...
CBER is unanimously against Elevdiys’ return to the market without additional evidence, according to media reports citing an ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results